Bladder cancer
NIAGARA-2
A Phase IIIb, Open-label, Single-arm, Global Study of Perioperative Durvalumab With Neoadjuvant ddMVAC or Gem/Cis in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)
Trial overview
Clinical Area
Medical Oncology
Disease
Bladder
Disease site
Genitourinary (GU)
Study Phase
III
Trial Identifiers
Registration number: NCT06960577
https://clinicaltrials.gov/study/NCT06960577
GenesisCare Location(s)
Principal Investigator(s)
Clinical trials enquiries